Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
8th grade Avg
|
|
New words:
Aberdeen, absence, absorb, accrued, ACIP, added, addressing, advocacy, AFandXyntha, Albany, ALK, allEmbeda, anaplastic, andAromasin, andEffexor, andEmbeda, andEmbedaare, andEnbrel, andFruit, andGeodon, andInlyta, andLipitor, andProNutrient, andRobitussin, andSMA, andSpiriva, andVfend, andViagra, andZyvox, apixaban, approvedSutent, Aromasin, art, asPrevnar, asserted, asViagra, atrial, austerity, authentic, axitinib, backlog, bar, BeneFIXandReFacto, BI, BIO, body, Bopriva, bosutinib, breached, British, bronchospasm, bull, Businessunder, buy, CA, captioned, captionedGeographic, captionGovernment, captionOperating, Catania, ceiling, Centrumand, CMS, Columbia, compromising, compulsory, Concomitantly, Conditionsbelow, Conductand, confidentiality, confront, constitutionality, Contingenciesfor, Contingenciesin, Corrupt, Court, coveringViagra, crizotinib, CT, CVD, CVMED, Danish, Databelow, deadline, deductible, deeper, defense, Deferral, deficit, degradation, deliberately, description, Descriptionsfor, Diego, digital, diminish, discontinued, discretionary, dispensed, divided, DOJ, donepezil, doubt, doubtful, dynamic, Eastern, Eater, Ecuador, Embeda, employee, entail, episode, evenly, excluded, excluding, exempt, exert, expenditure, explore, exploring, Exton, fallback, falsified, fashion, Ferrosan, fibrillation, forAricept, forAromasinin, forCaduetin, forCelebrex, forChampix, ForDetrol, forLipitorin, forlyrica, forSpiriva, forSpirivawill, forXalkori, foster, Fostera, FPT, fraudulently, frequently, fromSpirivaduring, FTC, fulfill, genitourinary, Gosport, graduated, grew, grown, guideline, HC, HCl, headingGovernance, headingsExecutive, headingsSection, hear, heart, helen, Hypoallergenic, identity, immunization, inadequate, inAricept, includingEnbrel, includingProbiotic, increasingly, Informationand, inItem, inPrevnar, instability, intensify, interpret, interruption, Investmentabove, IR, IRP, Israel, IVinjection, joint, Kendall, kinase, Korean, lag, Legislationsection, lifecycle, lifespan, lifestyle, Linsly, lowest, lymphoma, MA, Managementsection, Membershipand, MI, Mikael, mislabeled, MMA, MO, model, Monetary, naltrexone, nature, NC, neuroendocrine, newer, Nordic, Notably, numeric, observation, occupancy, ofAricept, ofCentrum, ofLipitorandCaduetin, ofLipitorbeginning, ofLipitorin, ofLyrica, ofManagement, ofPrevnar, OMB, Operationally, Operationssection, opinion, orour, ourEmbeda, ourGenotropinproduct, ourGold, ourLipitor, Outlook, overhaul, oversight, Overviewsection, Ownershipin, PA, pancreatic, PCV, PDUFA, penetration, Picky, pilot, placebo, placement, pNET, precaution, preclude, predominantly, premium, prioritizing, Productsbelow, prompted, properly, proprietary, provincial, quickly, Ranbaxy, Ratification, reauthorization, reauthorized, recall, regimen, regularly, Renegotiation, repurchase, rest, Revenuesin, Revenuessection, revolutionized, routine, Russia, School, scrutiny, secondary, SeeBiopharmaceutical, SeeGeneral, SeeGlobal, SeeItem, seeResearch, sellAricept, serotype, sheet, solvency, somatropin, source, stability, stable, steeper, sterile, Stringent, stroke, struck, subsidy, Supreme, temporarily, temporary, thatChantix, theAricept, theChampix, theOverview, thePremarin, thePrevnar, tiered, timeframe, timeline, toAriceptin, tofacitinib, tool, toPrevnar, toxicology, Transactionsand, Treasury, trillion, turbulence, Turkey, undesirable, uninspected, unlicensed, unpatented, unregulated, unresectable, unsanitary, upcoming, uptake, vacant, vast, Veggie, Veteran, whereEffexor, whetherPrevnar, withChantix, withdrew, withRevatio, worsening, yield
Removed:
amending, amortization, antifungal, beef, bloodstream, burt, California, captionedGeographicin, captionedPolicy, Carolina, Celebrex, cholesterol, clear, closer, conditional, conditionally, Connecticut, converted, dairy, depreciation, Developmentsin, disposition, enantiomeric, entitledFinancial, expiry, flow, Foodpolicy, headingAudit, headingDirector, headingPfizer, headingProduct, headingsReview, includingLipitor, inhibitor, initially, integrated, integrating, internationally, jeffrey, kind, kindler, longer, lowering, Lyrica, maintained, Managementin, Mediacom, medicinal, merger, Michigan, motivate, Natale, ofGenotropin, passed, PLF, protected, recession, Renewal, Ricciardi, robert, Shareholdersin, sharply, shortened, strictly, stronger, subsequently, theBlueprint, theFood, theRevenuessection, utilized, valuation, Viagra, Wagner
Filing tables
Filing exhibits
- 10-K Annual report
- 10.2 Pfizer Inc. 2004 Stock Plan, As Amended and Restated
- 10.5 Amended and Restated Nonfunded Supplement Retirement Plan
- 10.6 Amended and Restated Nonfunded Deferred Compensation and Supplement Savings Plan
- 10.11 Amended and Restated Wyeth Supplemental Employee Savings Plan
- 10.12 Amended and Restated Wyeth Supplemental Executive Retirement Savings Plan
- 12 Computation of Ratio of Earnings to Fixed Charges
- 13 Portions of the 2010 Financial Report
- 21 Subsidiaries of the Company
- 23 Consent of KPMG LLP, Independent Registered Public Accounting Firm
- 31.1 Certification by the Chief Executive Officer Pursuant to Section 302
- 31.2 Certification by the Chief Financial Officer Pursuant to Section 302
- 32.1 Certification by the Chief Executive Officer Pursuant to Section 906
- 32.2 Certification by the Chief Financial Officer Pursuant to Section 906
Related press release
PFE similar filings
Filing view
External links
Exhibit 32.2
Certification by the Chief Financial Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U. S. C. Section 1350, I, Frank A. D’Amelio, hereby certify that, to the best of my knowledge, the Annual Report on Form 10-K of Pfizer Inc. for the year ended December 31, 2011 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.
/s/ FRANK A. D’AMELIO
Frank A. D’Amelio
Executive Vice President, Business Operations and
Chief Financial Officer
February 28, 2012
This certification accompanies this Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.